Sensorion SA is a biopharmaceutical company, which engages in the development of therapies to treat and prevent diseases of the inner ear such as deafness, vertigo, and tinnitus. The company was founded by Christian Chabbert, Gilles Desmadryl, Sylvain Bartolami and Sophie Gaboyard in 2009 and is headquartered in Montpellier, France.
Fundamental metrics to determine fair value of the stock
Company’s recent performance and margins
Dividend yield, history and sustainability
Financial position and solvency of the company